Format

Send to

Choose Destination
See comment in PubMed Commons below
Neuropsychopharmacology. 2017 May;42(6):1179-1181. doi: 10.1038/npp.2016.193. Epub 2016 Sep 19.

Balancing the Promise and Risks of Ketamine Treatment for Mood Disorders.

Author information

1
Yale Depression Research Program, Yale University School of Medicine, New Haven, CT, USA.
2
Cure Alliance for Mental Illness, Providence, RI, USA.
3
Ketamine Advocacy Network, Seattle, WA, USA.
4
Baylor College of Medicine, Houston, TX and Michael E. Debakey VA Medical Center, Houston, TX, USA.
5
Mayo Clinic, Rochester, MN, USA.
6
University of Miami, Miami FL, USA.
7
Blue Cross of Idaho, Boise, ID, USA.
PMID:
27640324
PMCID:
PMC5437876
[Available on 2018-05-01]
DOI:
10.1038/npp.2016.193
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Support Center